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Effectiveness and cost-effectiveness of daily
all-over-body application of emollient
during the first year of life for preventing
atopic eczema in high-risk children (The
BEEP trial): protocol for a randomised
controlled trial
Joanne R. Chalmers1* , Rachel H. Haines2, Eleanor J. Mitchell2, Kim S. Thomas1, Sara J. Brown3,4, Matthew Ridd5,
Sandra Lawton6, Eric L. Simpson7, Michael J. Cork8, Tracey H. Sach9, Lucy E. Bradshaw2, Alan A. Montgomery2,
Robert J. Boyle10 and Hywel C. Williams1
Abstract
Background: Atopic eczema (AE) is a common skin problem that impairs quality of life and is associated with
the development of other atopic diseases including asthma, food allergy and allergic rhinitis. AE treatment is a
significant cost burden for health care providers. The purpose of the trial is to investigate whether daily application
of emollients for the first year of life can prevent AE developing in high-risk infants (first-degree relative with
asthma, AE or allergic rhinitis).
Methods: This is a protocol for a pragmatic, two-arm, randomised controlled, multicentre trial. Up to 1400 term
infants at high risk of developing AE will be recruited through the community, primary and secondary care in
England. Participating families will be randomised in a 1:1 ratio to receive general infant skin-care advice, or general
skin-care advice plus emollients with advice to apply daily to the infant for the first year of life. Families will not be
blinded to treatment allocation. The primary outcome will be a blinded assessment of AE at 24 months of age
using the UK Working Party Diagnostic Criteria for Atopic Eczema. Secondary outcomes are other definitions of AE,
time to AE onset, severity of AE (EASI and POEM), presence of other allergic diseases including food allergy, asthma
and hay fever, allergic sensitisation, quality of life, cost-effectiveness and safety of the emollients. Subgroup analyses
are planned for the primary outcome according to filaggrin genotype and the number of first-degree relatives
with AE and other atopic diseases. Families will be followed up by online and postal questionnaire at 3, 6, 12
and 18 months with a face-to-face visit at 24 months. Long-term follow-up until 60 months will be via
annual questionnaires.
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Discussion: This trial will demonstrate whether skin-barrier enhancement through daily emollient for the first year of
life can prevent AE from developing in high-risk infants. If effective, this simple and cheap intervention has the
potential to result in significant cost savings for health care providers throughout the world by preventing AE and
possibly other associated allergic diseases.
Trial registration: ISRCTN registry; ID: ISRCTN21528841. Registered on 25 July 2014.
Keywords: Protocol, Randomised controlled trial, Eczema, Atopic dermatitis, Prevention, Emollient, Barrier enhancement,
Filaggrin, Core outcomes
Background
Atopic eczema (syn. atopic dermatitis or eczema) [1] is a
very common chronic skin problem affecting 16 to 30%
of UK children and around 20% worldwide [2, 3]. Atopic
eczema usually starts in infancy and around 40% of cases
persist into adulthood, especially those with early onset
and widespread disease [4]. The family impact of caring
for a child with moderate or severe atopic eczema is
greater than that in caring for children with type 1
diabetes mellitus, mainly due to sleep deprivation,
employment loss, time to care for atopic eczema and
financial costs [5].
Children with atopic eczema, especially those with
severe disease, are at increased risk of also developing
other allergic (immunoglobulin E (IgE)-mediated) diseases
including food allergy, allergic asthma and allergic rhinitis
(hay fever) [6–8]. Eczema is often the first manifestation
of the so-called ‘atopic march’, in which a child progresses
from atopic eczema to food allergy, asthma and allergic
rhinitis later in life [9, 10]. Together, these atopic diseases
are the most common chronic diseases of childhood and
represent a major financial burden to the UK National
Health Service (NHS), with direct costs estimated at over
£1 billion per annum in 2004 [11]. There is a strong asso-
ciation between atopic eczema during infancy and the risk
of food allergy, with the highest prevalence of food allergy
reported in early onset and severe atopic eczema. A causal
link has been proposed [12], and this is supported by evi-
dence from mouse and human studies showing that sensi-
tisation to some foods can occur across a defective skin
barrier [13, 14].
Atopic eczema is highly heritable and shows strong
familial clustering. Prevalent mutations in the gene
encoding filaggrin (FLG), a key skin-barrier protein, rep-
resent the strongest and most consistent known genetic
risk factor for atopic eczema [15, 16].
Emollient (moisturiser) therapy is intended to improve
the barrier function of the skin. An emollient provides
lipids to the stratum corneum, which in turn, improves
skin hydration by trapping water. Emollients also help to
prevent inflammation caused by external irritants as evi-
denced by their benefit in preventing irritant occupa-
tional hand eczema [17]. In premature babies, emollients
have been shown to reduce the incidence of skin inflam-
mation [18], and in people with atopic eczema, to reduce
flares of atopic eczema (secondary prevention) [19].
Primary prevention is a highly desirable goal in a com-
plex chronic disease like atopic eczema with no cure. If
primary prevention of atopic eczema using a strategy of
early skin-barrier enhancement with simple low-cost
emollients is effective, it would represent a significant
cost saving for health care providers through reduced
treatment and appointment costs. Further cost savings
would result if early skin-barrier enhancement prevents
sensitisation and associated food allergy, asthma or aller-
gic rhinitis [11]. Even if the frequency of atopic eczema
cannot be significantly reduced, a shift in the severity
distribution of atopic eczema towards milder cases could
improve quality of life and reduce carer burden and
health care provider costs.
We carried out pilot studies to inform the design of
this trial. A functional mechanistic study provided evi-
dence for the choice of emollients for this trial and
showed they are not associated with any harm to the
skin barrier [20]. A multicentre, randomised controlled
pilot trial of 124 families showed that families found the
intervention acceptable and thus it would be feasible to
conduct a larger trial of emollients for the prevention of
atopic eczema [21]. Clinical outcomes showed that in-
fants in the emollient group had a significantly reduced
risk of developing atopic eczema by 6 months of age
compared to those in the control group (43% versus
22%, respectively, relative risk, 0.50; 95% CI, 0.28–0.90;
P = .017). A further trial from Japan that included 118
infants showed similar results, with 32% fewer infants in
the emollient group developing atopic eczema [22]. This
large, pragmatic trial (the Barrier Enhancement for
Eczema Prevention (BEEP) trial) described here is now
required to confirm the results seen in these small,
short-term trials and to establish the long-term effects of
emollients for preventing atopic eczema and associated
allergic diseases.
This is an abridged protocol based on protocol version
5.0 dated 26 October 2016. The full protocol is available on
the trial website [23]. This protocol adheres to the Standard
Protocol Items: Recommendations for Interventional Trials
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(SPIRIT) recommendations for interventional trials and the
SPIRIT Checklist is included (see Additional file 1).
Objectives
 The main objective is to determine whether
applying emollient daily to the entire body surface
area for the first year of life can prevent atopic
eczema in high-risk children
 Other objectives are to investigate:
○ Whether emollients can delay the onset and/or
reduce the severity in those who develop atopic
eczema
○ Whether emollients can prevent other allergic
diseases developing
○ The safety and cost-effectiveness of the preven-
tion strategy
○ The role of FLG genotyping as possible stratifier
of response to emollient intervention
Methods/design
Trial design
This is a randomised, controlled, two-arm (skin-care advice
plus emollient versus skin-care advice alone), parallel-
group, multicentre, assessor-blind trial (Fig. 1). It is a prag-
matic design in which investigators have no scheduled
contact with the families between randomisation and the
24-month visit in order to limit any influence on adherence,
minimise the risk of un-blinding and keep the research
nurse resources required to a reasonable level. All other
contact is with the trial coordinating centre (Figs. 2 and 3).
Screening for eligibility and the consent process is carried
out either antenatally or shortly after delivery. Further eligi-
bility checks are carried out post delivery prior to random-
isation which takes place within 3 weeks of delivery.
Setting
The trial is recruiting families across England. Identifica-
tion is via primary care (mailshot invitations to participate),
secondary care (through antenatal care, dermatology clinics
and posters), and in the community via direct advertising.
Recruiting sites are mainly secondary care centres, with a
smaller number of primary care centres involved. A list of
recruiting centres can be found in the acknowledgements.
Participants
Infants at high-risk of developing atopic eczema, defined
as having a first-degree relative with parent-reported
physician-diagnosed atopic eczema, asthma or allergic
rhinitis, are eligible for the trial. The infant must be no
more than 21 days old at the point of randomisation, the
mother must be aged at least 16 years and the consent-
ing adult must be able to understand English. Infants are
not eligible if they are born prior to 37 weeks’ gestation,
have a severe skin condition at time of randomisation
that would make it difficult to assess the skin for signs
of atopic eczema or that would preclude the use of
emollients (such as dystrophic epidermolysis bullosa,
ichthyosiform erythroderma or lamellar ichthyosis), or if
they have a serious health issue that would make partici-
pation difficult for the family (e.g. neonatal sepsis or
major congenital abnormalities). Only the first born of
any multiple births will be randomised.
Intervention
Both groups receive general skin-care advice to avoid
soap and bubble bath, use mild cleansers and shampoos
that have been specifically designed for babies, and avoid
using baby wipes based on NICE guidance on infant skin
care, July 2006 [24]. The use of bath oils is also discour-
aged unless directed to do so by a health care profes-
sional. Furthermore, the intervention group receives
additional advice to apply emollient daily for the first
year of life and are supplied with emollient free of
charge. Parents are able to choose between Doublebase
Gel® (Dermal Laboratories Ltd.) and Diprobase Cream®
(Merck Sharp & Dohme Ltd.) and can switch emollient
during the trial should they wish to. These emollients
were chosen because they have a similar formulation to
many emollient creams used in the UK, which would
mean that the results of this trial would be applicable to
a range of emollients with similar formulation and not
restricted to the two emollients used in this trial. Emol-
lients containing sodium lauryl sulphate (SLS) as an
emulsifier were specifically excluded because they have
Fig. 1 Schematic diagram showing the trial design and duration for participating families
Chalmers et al. Trials  (2017) 18:343 Page 3 of 11
been shown to have negative effects on the skin barrier
[25]. The skin-care advice for both groups is sent to
families within 2 days of randomisation in the form of a
booklet and a short online video. These materials will be
available as part of the final trial report.
The intervention group advice includes how to apply
the emollient; at least once daily all over the infant (the
scalp can be avoided) and the emollient should always
be applied bathing, even if it has previously been applied
that day. Parents are advised to start the emollient as
soon as possible after birth and definitely within 3 weeks
and the start date of emollient usage is recorded by the
trial coordinating centre during a routine 2-week post-
randomisation phone call. Emollient is continued until
the child is 1 year old and with parental reported usage
collected at 3, 6 and 12 months. The trial coordinating
centre keeps a record of the quantity of emollient pro-
vided to each participating family.
If the infant develops skin problems during the trial,
parents are advised to seek medical help in the usual
way. Any eczema that develops will be treated as per
normal practice regardless of treatment group allocation.
Primary outcome
The primary outcome is a diagnosis of atopic eczema at
24 months, defined as meeting the UK Working Party
Diagnostic Criteria for Atopic Eczema [26] which as-
sesses signs and symptoms present over the past year.
The criteria will be applied by a trained research nurse
blinded to treatment allocation. Applying these criteria
Fig. 2 Flowchart indicating participant flow through the trial
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when the infants are 24 months old will detect atopic ec-
zema that has developed between the ages of 12 and
24 months and will, therefore, exclude transient eczema-
tous rashes common in the first year of life that are
often not true atopic eczema. Measuring the outcome at
24 months also ensures that any observed effect on
reducing atopic eczema prevalence is a true preventative
effect rather than a treatment effect of the emollient
caused by shifting those with mild atopic eczema into
the subclinical range.
Secondary outcomes
The secondary outcomes relate to outcomes up to and
including the 24-month time point:
1. Presence of atopic eczema between birth and
24 months defined as:
(a) Parental report of a clinical diagnosis of
atopic eczema
(b) Parental completion of UK Working Party
Diagnostic Criteria for Atopic Eczema at 12 and
24 months (Additional file 2)
2. Presence of visible atopic eczema at 24 months
(assessed by a trained research nurse blinded to
treatment allocation)
3. Time to onset of atopic eczema:
(a) First parental report of a clinical diagnosis of
atopic eczema
(b) First topical corticosteroid and/or
immunosuppressant prescription for atopic
eczema
4. Severity of atopic eczema:
(a) Eczema Area and Severity Index (EASI)
(Additional file 3) at 24 months and
(b) Patient-oriented eczema measure (POEM)
(Additional file 4) at 12 and 24 months. EASI
and POEM are the core outcome instruments
Fig. 3 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure showing important events in the trial and their respective
time points. EASI - Eczema Area and Severity Index, POEM Patient Oriented Eczema Measure, EQ-5D-5 L – EuroQol Five Dimension, CHU-9D – The
Child Health Utility. 1The 24 month is a face-to-face visit from the research nurses blinded to treatment allocation. 2Hayfever status assessed at
60 month only. 3Washing practices only
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recommended by the Harmonising Outcome
Measures for Eczema (HOME) for measuring
clinician-reported signs and patient-reported
symptoms respectively [27, 28] and are both
well validated [29, 30]. The EASI will be
completed by a trained research nurse who
is blinded to treatment allocation
5. Presence of other allergic diseases:
(a) Parental-reported wheezing, allergic rhinitis and
food allergy symptoms, and parental report of a
clinical diagnosis of food allergy between 12 and
24 months
(b) Allergic sensitisation at 24 months to any of the
following common allergens: milk, egg, peanut,
cat, grass pollen, house dust mite
(c) Confirmed diagnosis of food allergy at
24 months to milk, egg, and/or peanut derived
from a combination of parental report, allergic
sensitisation and (if required) food challenge
6. Health-related quality of life:
(a) Child quality of life using the Child Health
Utility 9D (CHU-9D) at 24 months
(b) Parental quality of life measured using the
EuroQol-5D-5 L (EQ-5D-5 L) at baseline and
24 months
7. Health economic outcomes:
(a) Disease-related health care resource use
(b) Cost-effectiveness and cost-utility at 24 months
(combining health resource use and health-related
quality of life outcomes). If significantly more
effective than usual care at 24 months, a
longer-term economic model from birth to
16 years we be developed
Safety outcomes
Safety of the emollient determined from the number of
skin infections and infant slippage incidents related to
emollient use during the intervention period.
Tertiary outcomes
1. Parental opinion that their child has atopic eczema
at any point during the trial.
Data on tertiary outcomes 2–5 are collected at 36,
48 and 60 months:
2. Parental report of a clinical diagnosis of atopic eczema
3. Severity of atopic eczema (POEM)
4. Presence of other atopic diseases:
(a) Parental-reported wheezing, allergic rhinitis and
food allergy symptoms
(b) Parental report of a clinical diagnosis of asthma,
allergic rhinitis or food allergy
(c) Health-related quality of life (child; CHU-9D and
parent; EQ-5D-5 L)
5. Health economic outcomes:
(a) Disease-related health care resource use
(b) Cost-effectiveness and cost-utility (combining
health resource use and health-related quality of
life outcomes)
Randomisation, allocation concealment and blinding
The randomisation schedule (1:1 ratio) is based on a
computer-generated pseudo-random code using random
permuted blocks of randomly varying size. It was created
by the Nottingham Clinical Trials Unit (NCTU) and is
held on a secure University of Nottingham server. Dur-
ing the trial, access to the sequence is confined to the IT
programmer at NCTU. Randomisation is stratified by
recruiting centre and number of immediate family mem-
bers (parents or siblings) with atopic disease (1, 2, or
more than 2). Recruiting centre staff randomise partici-
pants via a web-based randomisation system developed
and maintained by NCTU. Recruiting centre staff are
not sent the results of the randomisation. It is not pos-
sible to blind parents as to which group they are in, but
the trial nurses conducting the skin examination at the
2-year visit are blinded to treatment allocation.
Study procedures and data collection
The screening and consent visit take place either in the
family home or at the recruiting site, depending on parent
preference, and consent obtained by the trial nurse (Figs. 2
and 3). Separate optional consent is obtained for the FLG
genotyping, skin-prick testing and food challenges. Ran-
domisation takes place after the infant is born and post-
birth eligibility checks are completed. Parents are sent
questionnaires online (or paper if requested) at 3, 6, 12, 18,
36, 48 and 60 months to collect outcome data. There is a
second face-to-face visit with the trial nurse at 24 months,
again in the family home or at the recruiting centre de-
pending on parent preference. At this 24-month visit the
blinded trial nurse conducts the skin examination for the
diagnostic criteria and the EASI, completes the question-
naires, and (where consent is given) takes the saliva sample
and carries out the skin-prick test. A summary of the data
collection can be found in Table 1: The schedule of trial as-
sessments. The trial nurses are fully trained in the diagno-
sis of atopic eczema and carrying out the EASI.
Saliva samples are collected via the child spitting into
a pot or swabs taken from the inside of the child’s cheek
and sent to the Centre for Dermatology and Genetic
Medicine, University of Dundee for deoxyribonucleic
acid (DNA) extraction by standard techniques and FLG
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genotyping for the most prevalent null mutations in the
white European population (2282del4, R501X, S3247X
and R2447X) according to published protocols [31]. The
skin-prick testing is carried out in line with the British
Society for Allergy and Clinical Immunology procedures
[32] and the following allergens are tested; grass pollen
mix, dust mite and cat (Allergopharma, Germany), pea-
nut (Inmunotek, Spain), fresh skimmed cow’s milk and
fresh chicken egg. Positive (1% histamine) and negative
(0.9% saline) controls will also be used (Allergopharma,
Germany). The trial nurses are fully trained in conduct-
ing skin-prick tests and emergency procedures in the
highly unlikely event of any serious allergic reactions.
Participants with a positive skin-prick test or history
suggestive for food allergy in whom further investigation
is required for a diagnosis of food allergy to be made are
invited for a supervised oral food challenge conducted
by experienced allergy nurses following standard proce-
dures who are blinded to treatment allocation. The pres-
ence of a clinical reaction is determined using modified
PRACTALL and iFAAM criteria [33, 34].
A methodological two-by-two factorial substudy is
nested within this trial to investigate the effectiveness of
interventions designed to improve rates of follow-up data
collection. The interventions are SMS text message notifi-
cations that the questionnaires will be sent by email or
post the following day versus no text message and the £10
inconvenience voucher either sent to parents either before
the visit, or given at the 24-month visit. Full details can be
found in the Studies Within A Trial (SWAT) registry [35].
Small tokens of appreciation and birthday cards are
sent to all participating families throughout the trial to
promote retention, and the trial coordinating centre will
make every effort to keep the parents contact details up
to date throughout the trial. When questionnaires are
not completed online or by post, families are telephoned
by trial coordinating centre staff. Families wishing to
withdraw from the intervention are encouraged to con-
tinue to provide data on the main outcomes, with par-
ticular importance placed on the 24-month face-to-face
visit where the primary outcome data is collected.
Where a face-to-face visit is not possible (e.g. the family
have moved abroad) key outcomes are collected via re-
mote means (e.g. telephone, text, email or post).
Data will be entered directly onto the database by the
trial nurses or parents via online questionnaires. All data
are treated confidentially and held on a secure University
of Nottingham server with restricted and password-
protected access. Questionnaires and other data collection
forms will be available as part of the final trial report.
Sample size calculation
The sample size calculation was carried out using Stata
[36, 37]. A total of 1282 infants are required to detect a
relative reduction of 30% in the intervention group in
the number of infants who developed atopic eczema in
the previous year (between 12 and 24 months of age) at
the 5% significance level (two-sided) with 90% power
based on an expected rate of 30% in the control group
and allowing for 20% attrition at 24 months. This rela-
tive reduction is considered a conservative estimate; re-
sults of the pilot study showed a 50% reduction in atopic
eczema at 6 months (43% developed atopic eczema in
the control group (n = 55) compared to 22% in the emol-
lient group (n = 53), 95% CI 0.28 to 0.9) [21]. The effect
size is anticipated to be lower in this main trial than in
the pilot due to the more pragmatic trial design and the
longer-term outcome assessment.
Recruitment began in November 2014 and ended in
November 2016. A sample size review by the TSC took
place after 21 months of recruitment to check the atopic
eczema rate in the control group and attrition. As re-
cruitment had progressed better than expected, the TSC
advised that no additional families should be consented
to the trial, but those who had already consented to the
trial should continue to be randomised. The total num-
ber randomised at that point was expected to be
approximately 1400.
Planned analysis
Analysis of the primary, secondary and safety out-
comes will be performed when all the 24-month data
have been collected. The longer-term tertiary out-
comes will be analysed once data collection is
complete for the 60-month follow-up.
The main approach to all analyses will be to analyse
participants as randomised (intention-to-treat), regard-
less of adherence with allocation and without imputation
for missing data. All analyses will be carried out using
Stata/SE 13 or above [36].
The primary outcome will be analysed using a general-
ised linear model adjusting for stratification variables.
The difference between the two groups will be sum-
marised using a relative risk with 95% confidence
intervals. Sensitivity analyses will be performed using
multiple imputation for missing outcomes by including
any prognostic variables showing a baseline imbalance in
the model and accounting for actual emollient use.
Analyses of secondary and long-term outcomes will use
appropriate regression models depending on the type of
outcome and differences between the two groups
summarised with 95% confidence intervals. Descriptive
analysis of safety endpoints will be presented both
according to randomised group and according to actual
emollient use in the two groups. Planned subgroup ana-
lyses will be conducted by including an interaction term
in the regression analysis for the primary outcome
according to: (1) whether an individual is FLG-wild-type
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genotype or whether they have one or two of the
screened FLG null mutations, (2).the number of immedi-
ate family members with atopic disease and (3) the num-
ber of immediate family members with atopic eczema.
Full details of the analyses and potential sensitivity
analyses for the food allergy/sensitisation outcomes will
be documented in the Statistical Analysis Plan prior to
any analysis and made publicly available on the trial
website [23].
Economic evaluation
Economic evaluations will be conducted to estimate the
cost-effectiveness of the intervention from an NHS per-
spective in the short term (24 months within trial ana-
lysis), medium term (60 months within trial analysis)
and, if appropriate, longer term (birth to 16 years using
a model-based analysis). For the within trial analyses,
the incremental cost per atopic eczema case prevented,
incremental cost per quality-adjusted life year (QALY)
based on CHU-9D (parental-proxy reported), and incre-
mental cost per QALY based on main carer own health-
related quality of life (EQ-5D-5 L) will be estimated. An
incremental cost-effectiveness analysis will be performed
using accepted methods with data reported in a disag-
gregated way [38–41]. Analysis of uncertainty will follow
recommended practice with results presented as cost-
effectiveness acceptability curves [42, 43]. If the inter-
vention is significantly more effective at 24 months than
normal practice, a longer-term economic model taking
an NHS perspective will be developed for the economic
costs and benefits of the intervention for a single birth
cohort from birth to 16 years using trial data, within-
trial cost-effectiveness analyses using data collected dur-
ing the first 24 months and at 36, 48 and 60 months,
other published data, expert opinion and population
datasets (where appropriate and available).
Trial oversight
Trial oversight is provided by the Trial Steering
Committee (TSC) which comprises an independent chair
and three independent members (including one patient
representative). Further details can be found in the
‘Acknowledgements’ section. A separate Data Monitoring
Committee is not required due to the very low risk associ-
ated with the intervention, so this function will be covered
by the TSC.
Discussion
This trial of up to 1400 infants at high-risk of developing
atopic eczema will investigate whether daily, all-over ap-
plication of emollients (of a defined type of formulation)
from birth for the first year of life can prevent atopic ec-
zema developing by 2 years of age, and whether any such
preventive effects are maintained or are reduced up to
the age of 5 years. It will also show whether the inter-
vention can delay the onset of atopic eczema, or whether
it alters the severity distribution towards milder disease.
The effect on any other atopic conditions associated
with atopic eczema (allergic rhinitis, asthma and food
allergy) will also be assessed. By assessing the FLG geno-
type of participants, the extent to which any effect of
emollients can be modified by filaggrin haploinsuffi-
ciency will also be determined. Any differential effect
according to FLG genotype could be used for a persona-
lised approach to the future use of emollient for the
prevention of atopic eczema.
We have taken a pragmatic approach to all aspects of
this trial including a limited number of exclusion cri-
teria, interfering as little as possible in the use of the
emollient, minimal follow-up and an intention-to-treat
analysis. However, as with all pragmatic trials, there are
some limitations. Families participating in the trial are
likely to be more motivated to use the emollients than
the average population. Even so, we may observe a null
result due to poor adherence because of the pragmatic
nature of the advice to use emollients, whereas the inter-
vention may be effective under conditions that enhance
adherence. We have included only families whose child
is at higher risk of developing eczema due to family his-
tory of atopy, although other groups are planning trials
in unselected-for risk populations. Also, we have only
offered two emollients in this trial, but there are many
others commonly prescribed or purchased by parents. If
the trial demonstrates that this relatively cheap and sim-
ple intervention is effective in preventing atopic eczema,
uptake of the intervention will result in reduced costs
for health care providers such as the UK National Health
Service. Furthermore, if any effect is extended to the
prevention of other atopic conditions then the cost
savings could be significantly greater.
The results of the trial will be submitted for publication
in peer-reviewed journals and the National Institute for
Health Research (NIHR) journal series, and disseminated
to health care providers and professional groups including
health visitors, midwives, GPs, dermatologists and com-
missioners. Health care providers and professionals will
then have the evidence required to make funding and
health care decisions about emollients for preventing
atopic eczema. We will inform all trial participants of the
results of the main 2-year analysis and 5-year analysis and
we will also post our results on the trial register. A variety
of media outlets will be used to disseminate the results
directly to pregnant women and new parents. Parents are
often anxious to know whether their children will develop
atopic eczema, especially those with experience of atopic
eczema, and are keen to know what they can do minimise
the risk. The results of this trial will help inform families
whether emollients are an effective prevention strategy.
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Other trials of emollients and related interventions for
the prevention of atopic eczema are being undertaken
throughout the world, and we have formed a collabora-
tive group to undertake a prospectively planned meta-
analysis (PPMA) of such studies [44]. Other investigators
interested in collaborating in such a PPMA should
contact this trial team directly.
Current trial status
Recruiting.
Additional files
Additional file 1: Checklist: recommended items to address in a clinical
trial protocol and related documents*. (DOC 121 kb)
Additional file 2: Diagnostic criteria (UK Working Party Diagnostic
Criteria for Atopic Dermatitis). (DOCX 11 kb)
Additional file 3: The Eczema Area and Severity Index (EASI); clinician-
reported signs severity scale. (DOCX 15 kb)
Additional file 4: The Patient Oriented Eczema Measure (POEM);
patient-reported symptoms severity scale. (DOCX 1521 kb)
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